Baseline characteristics
| Characteristic . | Entire cohort (n = 198) . | Patients requiring admission (n = 178) . | Patients who died (n = 66) . | |||
|---|---|---|---|---|---|---|
| Proportion (unless otherwise specified) . | Number with available data . | Proportion (unless otherwise specified) . | Number with available data . | Proportion (unless otherwise specified) . | Number with available data . | |
| Age (y) at CLL diagnosis, median (range) | 63 (35-92) | 195 | 63 (35-92) | 175 | 65 (40-92) | 65 |
| Age (y) at COVID-19 diagnosis | 198 | 178 | 66 | |||
| Median (range) | 70.5 (38-98) | 71 (41-98) | 73 (43-98) | |||
| ≥65 y | 67% | 68% | 71% | |||
| ≥75 y | 36% | 37% | 47% | |||
| Male | 63% | 198 | 62% | 178 | 59% | 66 |
| White | 88% | 196 | 90% | 177 | 92% | 65 |
| CIRS | 171 | 156 | 58 | |||
| Median (range) | 8 (4-32) | 8 (4-32) | 9 (4-32) | |||
| >6 | 67% | 67% | 81% | |||
| Comorbidities | ||||||
| Hypertension | 51% | 198 | 51% | 178 | 56% | 66 |
| Coronary artery disease | 13% | 192 | 13% | 172 | 14% | 63 |
| Arrhythmia | 20% | 197 | 23% | 177 | 25% | 65 |
| Diabetes | 20% | 198 | 20% | 178 | 32% | 66 |
| COPD | 11% | 198 | 11% | 178 | 14% | 66 |
| Asthma | 6% | 197 | 7% | 177 | 11% | 65 |
| Chronic renal disease | 17% | 198 | 18% | 178 | 24% | 66 |
| Autoimmune disease | 10% | 198 | 10% | 178 | 9% | 66 |
| Hypogammaglobulinemia | 44% | 177 | 45% | 157 | 36% | 58 |
| Smoking history | 196 | 176 | 66 | |||
| Never smoker | 66% | 65% | 65% | |||
| Former smoker | 27% | 28% | 23% | |||
| Current smoker | 7% | 7% | 12% | |||
| Labs at COVID-19 diagnosis | ||||||
| Absolute neutrophil count (thousand cells/μL), median (range) | 4.6 (0.0-33.5) | 184 | 4.7 (0.3-33.5) | 169 | 4.8 (0.4-25.9) | 61 |
| Absolute lymphocyte count (thousand cells/μL), median (range) | 7.8 (0.0-579) | 185 | 7.8 (0.0-579) | 170 | 11.6 (0.2-253) | 62 |
| CLL treatment history | 195 | 175 | 68 | |||
| Never treated | 39% | 39% | 42% | 66 | ||
| Prior therapy | 61% | 61% | 58% | |||
| Lines of therapy for previously treated patients, median (range) | 2 (1-8) | 119 | 2 (1-8) | 107 | 2 (1-8) | 38 |
| Prior fludarabine or bendamustine | 28% | 183 | 28% | 164 | 26% | 61 |
| Receiving therapy at time of COVID-19 diagnosis | 45% | 198 | 46% | 178 | 38% | 66 |
| Characteristic . | Entire cohort (n = 198) . | Patients requiring admission (n = 178) . | Patients who died (n = 66) . | |||
|---|---|---|---|---|---|---|
| Proportion (unless otherwise specified) . | Number with available data . | Proportion (unless otherwise specified) . | Number with available data . | Proportion (unless otherwise specified) . | Number with available data . | |
| Age (y) at CLL diagnosis, median (range) | 63 (35-92) | 195 | 63 (35-92) | 175 | 65 (40-92) | 65 |
| Age (y) at COVID-19 diagnosis | 198 | 178 | 66 | |||
| Median (range) | 70.5 (38-98) | 71 (41-98) | 73 (43-98) | |||
| ≥65 y | 67% | 68% | 71% | |||
| ≥75 y | 36% | 37% | 47% | |||
| Male | 63% | 198 | 62% | 178 | 59% | 66 |
| White | 88% | 196 | 90% | 177 | 92% | 65 |
| CIRS | 171 | 156 | 58 | |||
| Median (range) | 8 (4-32) | 8 (4-32) | 9 (4-32) | |||
| >6 | 67% | 67% | 81% | |||
| Comorbidities | ||||||
| Hypertension | 51% | 198 | 51% | 178 | 56% | 66 |
| Coronary artery disease | 13% | 192 | 13% | 172 | 14% | 63 |
| Arrhythmia | 20% | 197 | 23% | 177 | 25% | 65 |
| Diabetes | 20% | 198 | 20% | 178 | 32% | 66 |
| COPD | 11% | 198 | 11% | 178 | 14% | 66 |
| Asthma | 6% | 197 | 7% | 177 | 11% | 65 |
| Chronic renal disease | 17% | 198 | 18% | 178 | 24% | 66 |
| Autoimmune disease | 10% | 198 | 10% | 178 | 9% | 66 |
| Hypogammaglobulinemia | 44% | 177 | 45% | 157 | 36% | 58 |
| Smoking history | 196 | 176 | 66 | |||
| Never smoker | 66% | 65% | 65% | |||
| Former smoker | 27% | 28% | 23% | |||
| Current smoker | 7% | 7% | 12% | |||
| Labs at COVID-19 diagnosis | ||||||
| Absolute neutrophil count (thousand cells/μL), median (range) | 4.6 (0.0-33.5) | 184 | 4.7 (0.3-33.5) | 169 | 4.8 (0.4-25.9) | 61 |
| Absolute lymphocyte count (thousand cells/μL), median (range) | 7.8 (0.0-579) | 185 | 7.8 (0.0-579) | 170 | 11.6 (0.2-253) | 62 |
| CLL treatment history | 195 | 175 | 68 | |||
| Never treated | 39% | 39% | 42% | 66 | ||
| Prior therapy | 61% | 61% | 58% | |||
| Lines of therapy for previously treated patients, median (range) | 2 (1-8) | 119 | 2 (1-8) | 107 | 2 (1-8) | 38 |
| Prior fludarabine or bendamustine | 28% | 183 | 28% | 164 | 26% | 61 |
| Receiving therapy at time of COVID-19 diagnosis | 45% | 198 | 46% | 178 | 38% | 66 |
COPD, chronic obstructive pulmonary disease.